The investment was led by London-based West Hill Capital.
West Hill Capital, with over £20B in advised transactions, specialises in capital raisings, IPOs, and M&A. The firm executes smaller transactions with capital raisings ranging from £1M to £20M.
“Saving hearts and minds”
According to Neurescue, the current CPR method only replaces 35 per cent of blood flow, often insufficient for effective resuscitation, and fails to provide enough time for advanced treatments.
Cardiac arrest, contributing to 15-20 per cent of all deaths, sees a survival rate of just 1 in 10 with existing treatments. In the US, sudden cardiac arrest represents 40-50 per cent of all life years lost from cardiac diseases.
The standard CPR and AEDs do not achieve the necessary blood pressure to resuscitate most patients or allow sufficient time for advanced interventions. Accidents are the leading cause of death under 45, with critical bleeding accounting for a third; an unmet need exists for improved tools to address these cases.
This is where Neurescue looks to make a difference.
The company specialises in cardiovascular solutions, particularly the world’s first computer-aided balloon catheter for aortic occlusion. This technique aims to enhance blood flow to the brain and heart, increasing resuscitation rates and providing additional treatment time.
The nine-year-old company was founded by Dr. Habib Frost and received FDA approval two and a half years ago for its NEURESCUE device.
The NEURESCUE device, consisting of a catheter and control unit, employs patented sensor guidance and automated inflation technology. Its safety feedback system ensures precise positioning and regulates balloon pressure, preventing damage.
In emergency situations, the device supercharges blood flow to the heart and brain within one minute, addressing critical scenarios with a simple yet effective design.